HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY

Geert R. D'Haens  ¹     Bruce E. Sands  ²     Remo Panaccione  ³     Chenglong Han  ⁴     Susana Gonzalez  ⁵     Kathleen Weisel  ⁵     Mary Ellen Frustuaci  ⁵     Zijiang Yang  ⁵     Aparna Sahoo  ⁵     Anita Afzali  ⁶     Jane Andrews  ⁷     Silvio Danese  ⁸     Tadakazu Hisamatsu  ⁹     Brian G. Feagan  ¹⁰     Julian Panés  ¹¹     Walter Reinisch  ¹²     William Sandborn  ¹³     David T. Rubin  ^14    
1 Amsterdam UMC, Amsterdam, Netherlands
² Icahn School of Medicine at Mount Sinai, New York, United States
³ University of Calgary, Calgary, Canada
⁴ Janssen Global Services, LLC, Malvern, United States
⁵ Janssen Research & Development, LLC, Spring House
⁶ The Ohio State University Wexner Medical Center, Columbus, United States
⁷ Royal Adelaide Hospital & University of Adelaide, Adelaide
⁸ IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
⁹ Kyorin University, Tokyo, Japan
¹⁰ Alimentiv Inc., London, Canada
¹¹ Hospital Clínic Barcelona, Barcelona, Spain
¹² Medical University of Vienna, Vienna, Austria
¹³ University of California San Diego, San Diego, United States
¹⁴ University of Chicago Medicine, Chicago, United States

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)